Personal profile


Dr. Anderly Chüeh is a Research Fellow in the Department of Biochemistry and Molecular Biology (Monash University). Dr Chüeh specializes in cancer biomarker discovery and small molecule drug development. During his PhD in Professor KH Andy Choo’s laboratory at the Murdoch Children’s Research Institute (University of Melbourne), he developed novel 2-colour genomic tiling PCR-fragment microarray techniques for high-resolution detection of chromosomal aberrations in human patient samples – a technology that was subsequently transferred to Victorian Clinical Genetics Services (VCGS) for routine molecular diagnosis of chromosomal aberrations in human patients.

In 2009, the Ludwig Institute of Cancer Research (Melbourne Centre for Clinical Sciences) offered him a Postdoctoral Fellowship in Professor John Mariadason’s laboratory, where he mastered the different aspects of colon cancer cell biology and therapeutics. His work on histone deacetylase inhibitors (HDACi) in cancers identified a novel transcriptional axis that is predictive of HDACi drug sensitivity across tumours, defining the molecular basis for sensitivity or resistance to HDACi and established a strategy for overcoming inherent resistance to HDACi by rational combination with BCL-xL inhibitors.

Completing his postdoctoral fellowship in 2013, he joined the Walter and Eliza Hall Institute (WEHI) where he worked as a Senior Research Scientist within the Cancer Therapeutics CRC and the start-up biotech company CTx CRC Limited on industry projects, contributing to high throughput drug screening, biomarker identification and target validation on multiple drug discovery pipelines that successfully licensed novel small molecules to multinational pharmaceutical companies, including Merck and Pfizer.

In 2019, Dr Chüeh joined the laboratory of Professor Roger Daly in Monash University as a Research Fellow. Dr Chüeh’s goal is to drive to academic discoveries into clinical translation in the form of new small molecule-based cancer therapies and clinical companion biomarkers – a research vision that is facilitated by cutting-edge high-throughput screening (HTS) technologies, chemical genetics and proteomics approaches, and human genetically modified cell lines and mouse models as tools for therapeutic target validation, biomarker discovery and small molecule drug development.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Human Genetics (Paediatrics), Ph.D, University of Melbourne

1 Mar 20041 Sept 2008

Award Date: 15 Dec 2008

Human Development and Disease Program (Paediatrics), B.BiomedSc Honours, University of Melbourne

3 Mar 200331 Dec 2003

Award Date: 7 Apr 2004

Biochemistry and Molecular Biology, B.BiomedSc, University of Melbourne

6 Mar 200013 Dec 2002

Award Date: 5 Mar 2003

Research area keywords

  • Mitotic Signaling
  • Epigenetic Enzymes
  • Molecular Oncology
  • Biomarkers
  • Drug Discovery
  • Translation Science

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or